GlassScriptPhysician profile
Ashleigh Emkin
NPI 1225882921
$4,134.39
in general payments reported to CMS, 2019-2025
39 companies · $3,800 in 2025
The $3,800 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $334 · 2025: $3,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,553 · Education: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,553.35 |
| Education | $581.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $426.36 | 2024-2025 | Rybrevant, Erleada, Carvykti |
| Pfizer INC. | $300.27 | 2025 | |
| Incyte Corporation | $283.06 | 2025 | Jakafi, Monjuvi, Zynyz |
| Beone Medicines USA, INC. | $263.16 | 2025 | Brukinsa, Tevimbra |
| Astrazeneca Pharmaceuticals LP | $255.11 | 2025 | Datroway, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $210.63 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Glaxosmithkline, LLC. | $185.10 | 2024-2025 | Jemperli, Ojjaara |
| Novartis Pharmaceuticals Corporation | $182.19 | 2025 | |
| Sobi, INC | $164.76 | 2025 | |
| Immunocore Limited | $137.00 | 2025 | Kimmtrak |
| E.R. Squibb & Sons, L.L.C. | $135.26 | 2025 | Breyanzi |
| Abbvie INC. | $134.33 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $128.90 | 2025 | Myrisk |
| Genzyme Corporation | $96.76 | 2025 | |
| Sanofi-Aventis U.S. LLC | $91.00 | 2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $87.09 | 2025 | Reblozyl |
| Adc Therapeutics America, INC. | $84.33 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.79 | 2025 | Alunbrig, Fruzaqla, Ninlaro |
| Seagen INC. | $83.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $75.45 | 2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $73.50 | 2025 | |
| Beigene USA, INC. | $69.42 | 2025 | Tevimbra, Brukinsa |
| Gilead Sciences, INC. | $67.61 | 2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $47.11 | 2025 | |
| Geron Corporation | $45.73 | 2025 | Rytelo |
| Genentech USA, INC. | $44.51 | 2024-2025 | Polivy, Phesgo, Itovebi |
| Coherus Oncology, INC. | $40.25 | 2025 | Loqtorzi |
| Blueprint Medicines Corporation | $37.50 | 2025 | Ayvakit |
| Caris Mpi, INC. | $37.02 | 2025 | Mi Cancer Seek |
| Eisai INC. | $36.20 | 2024 | |
| Legend Biotech USA INC. | $34.32 | 2025 | Carvykti |
| Array Biopharma INC | $33.87 | 2025 | Braftovi, Tukysa, Mektovi |
| Regeneron Healthcare Solutions, INC. | $29.36 | 2025 | Libtayo |
| Tersera Therapeutics LLC | $27.65 | 2025 | Zoladex |
| Daiichi Sankyo INC. | $25.89 | 2025 | Enhertu |
| Puma Biotechnology, INC. | $22.47 | 2025 | |
| Karyopharm Therapeutics INC. | $21.04 | 2025 | Xpovio |
| Stemline Therapeutics INC. | $19.79 | 2025 | Orserdu |
| Janssen Scientific Affairs, LLC | $13.60 | 2025 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashleigh Emkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.